Details
Category: Volume 05 Issue 12 December 2017
Hits: 1981

Title: Cost Variation Study of Various Brands of Anti-Asthmatic Drugs Available in India

Authors: Jyoti B. Gadhade, Yogesh B. Magar, Rajesh S. Hiray, Balasaheb B. Ghongane

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i12.120

Abstract

Objective: Asthma is chronic inflammatory disorder of lungs that affects people of all ages and is a significant source of morbidity and mortality worldwide. It requires continuous medical care. Higher and unaffordable drug prices are among the major reasons for non-compliance and resultant treatment failure. The cost of drugs plays a major role in patient’s care especially in developing countries. It has been observed that there is a gross variation in the cost of different brands of same generic drug. If doctors are not aware, then they may prescribe costly brands, which ultimately lead to non-adherence. The present study was planned to get some idea about cost differences in various brands of anti-asthmatic drugs.

Methods: The minimum and the maximum cost in Rupees (INR) of a particular anti-asthmatic agent manufactured by various pharmaceutical companies in the same strength were noted from latest issue of Drug today 2017. The cost ratio and percentage cost variation were noted for each brand.

Results: This study showed a noticeable variation in the prices of anti-asthmatic drugs. The highest percent cost variation was found for Doxophylline400mg(3100%), followed Deflazacort 6mg(1300%), Methylprednisolone 4mg (1104%), Combination of Formoterol and Budesonide (444%), Salbutamol 4mg caps(363%), Theophylline and Salbutamol combination(236%), Ketotifen 1mg(217%).The lowest percent cost variations found were: Fluticasone 50mcg(0.4%), Cromolyn 20mg(2%), Formoterol12mcg(11.5%), Tiotropium 18 mcg(11.5%), Ipratropium 20mcg/200mdi(19%) etc.

Conclusion: Government should look into the pricing control policy of anti-asthmatic drugs manufactured by various companies in India, so that pricing of various brands remains uniform, quality assured and affordable. Doctors must prescribe rationally, choosing cost effective medicines based on country`s health situation.

Keywords: Anti-asthmatic Drugs, Non-Compliance, Adherence, Cost Variation, Rational.

References

  1. Sakthivel S. Access to essential drugs and medicines. In: Lal PG, editor. National Commission on Macroeconomics and Health. New Delhi: Ministry of Health; 2005. p. 185-210.
  2. Sundaram VM. Pharma industry in India. Drug News Perspect 2008;21(1):59-63.
  3. Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci 2013;2(1):63-9.
  4. Paunikar AP, Bhave KA. Cost analysis of oral antidepressant drugs available in India. Natl J Physiol Pharm Pharmacol 2015;5(5):1-5.
  5. Ravi Shankar P, Subish P. Ambiguous pricing of topical dermatological products: A survey of brands from two South Asian countries. J Pak AssocDermatol 2006;16:134-40.
  6. Lallan HN, Borde MK, Ray IM, Deshmukh YA. Cost variation study of antidiabetics: Indian scenario. Indian J Appl Res 2014;4(5):420-1.
  7. Sweta TB, Kiran BA. Cost analysis of oral antipsychotic drugs available in the indian market. Int J Pharm Sci Rev Res 2015;29(2):267-70.
  8. Global Initiative for Asthma (GINA): Pocket guide for asthma management and prevention. Available at http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2015.pdf. Accessed on 16.09.2017.
  9. McFadden ER Jr. Asthma In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS (Eds.). Harrison’s Principles of Internal Medicine, 16th edn. New York: McGraw-Hill, 2005. pp. 1508–16.
  10. World Health Organization. Fact sheet (N0206): Bronchial asthma. Available at http://www.who.int/mediacentre/factsheets/fs206/en/ Accessed on 14.12.2017.
  11. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;19;9:24.
  12. Global Asthma Network: The Global Asthma Report 2014. http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf. Accessed on 14.12.2017.
  13. World Health Organization. Trade, foreign policy, diplomacy and health: Access to medicine. Available at http://www.who.int/trade/glossary/story002/en/ Accessed on 15.12.2017.
  14. Gupta RK, Reddy PS. A calm look on cost analysis of different brands of anti-epileptic drug. J MGIMS. 2011;16(i):64-6.
  15. Bhushan B, Gaude G. Study to assess factors contributing to compliance of aerosol therapy in bronchial asthma. Internet J Pulm Med. 2009;12(1):1-6.
  16. Kardas P, Bishai WR. Compliance in infective medicine. Adv Stud Med. 2006;6(7C):S652-8.9.
  17. World Health Organization: Workshop on differential pricing and financing of Essential Drugs. https://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/35balasubramaniam_e.doc Accessed on 15.12.2017.
  18. Drug Today. October-December 2017;23(2):867-89.
  19. PharmaSahi Dam. App version 2.0 National Pharmaceutical Pricing Authority, GOI, National Informatics Centre. Accessed on 15.12.2017
  20. Planning Commission Govt. of India 2014. Report of the expert group to review the methodology for measurement of poverty. Available at http://planningcommission.nic.in/reports/genrep/pov_rep0707.pdf. Accessed 12.12.2017.
  21. Uppsala universitet. Economical access to antibiotics in an era of increasing resistance - a study from Lahore, Pakistan (CR). Available at http://www.farmfak.uu.se/farm/exjob/diplomawork/VT10BinaAzhar.pdf. Accessed 12.12.2017.
  22. Piette JD, Beard A, Rosland AM, McHorney CA. Beliefs that influence cost-related medication nonadherence among the “haves” and “have nots” with chronic diseases. Patient Prefer Adherence. 2011;5:389-96.
  23. Management Sciences for Health (MSH). Evaluating the cost of pharmaceuticals. 2007. Available at http://www.who.int/medicines/technical_briefing/tbs/06-TG_Evaluating-drug-costs_final-08.pdf. Accessed 12.12.2017.
  24. SCOPE: Pharmacist's Guide to Judicious Usage ofAntibiotics.https://cme.dannemiller.com/scope/articles/activity?id=428&p=12. Accessed 12.12.2017.
  25. PR Newswire: Higher Out-of-Pocket Costs Cause Massive Non-Compliance in the Use of Prescription Drugs, and This Is Likely to Grow. Available at http://goo.gl/2ClISI. Accessed 14.12.2017.
  26. Andayani TM, Imaningsih I. Cost analysis of antidiabetic drugs for diabetes mellitus out patient in Kodya Yogyakarta hospital. Malay J pharm Sci. 2007;5(1):19-23.
  27. Allan GM, Lexchin J, Wiebe N. Physician awarenessof drug cost: A systematic review. PLoS Med.2007;4(9):e283.

Corresponding Author

Rajesh S. Hiray

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Contact No. +91-9422330982